Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › RGT-075 phase 2b

RGT-075 phase 2b

RGT-075 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
RGT-075
Population
obesity
Phase
2b
Duration
36 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
RGT-075 180 mg oralobesity36—−10.4 % vs −1.6 %
Δ −8.8 pp
−10.4 % vs −1.6 %
Δ −8.8 pp
——————−9.9 vs +0.0verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (1)
  • RGT-075 180 mg oral · weight_eff · Abstract, Results
    treatment with RGT-075 at 180 mg resulted in a least-square mean percent body-weight reduction of 10.4%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: RGT-075 phase 2b. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/rgt-075-phase-2b/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.